Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12

Proteins: Structure, Function and Genetics

Volumn 70, Issue 4, 2008, Pages 1461-1474

  Ryan, Daniel P ^a   Duncan, Jaimee L ^a   Lee, Christopher ^a   Kuchel, Philip W ^a   Matthews, Jacqueline M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

LMO2; Protein DNA complex; Protein protein interactions; T cell leukaemia; TAL1

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; E PROTEIN 12; HOMODIMER; LIM DOMAIN BINDING PROTEIN 1; LIM ONLY PROTEIN 2; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T CELL LEUKEMIA;

EID: 39749171110     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21638     Document Type: Article

References (57)

1. 1 Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, Lander ES, Golub TR, Look AT. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002 ; 1: 75–87.
2. 2 Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 1999 ; 93: 2760–2770.
3. 3 Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine‐rich LIM‐domain oncogenes: distinct members are involved in T‐cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 1991 ; 88: 4367–4371.
4. 4 Larson RC, Fisch P, Larson TA, Lavenir I, Langford T, King G, Rabbitts TH. T cell tumours of disparate phenotype in mice transgenic for Rbtn‐2. Oncogene 1994 ; 9: 3675–3681.
5. 5 Kelliher MA, Seldin DC, Leder P. Tal‐1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J 1996 ; 15: 5160–5166.
6. 6 Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I, Nottage K, Rabbitts TH. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 1996 ; 15: 1021–1027.
7. 7 Massari ME, Murre C. Helix‐loop‐helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000 ; 20: 429–440.
8. 8 Bach I. The LIM domain: regulation by association. Mech Dev 2000 ; 91: 5–17.
9. 9 Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, Okamoto Y, Tokita H, Ohira M, Nakagawara A. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 2005 ; 65: 4587–4597.
10. 10 Rabbitts TH. LMO T‐cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev 1998 ; 12: 2651–2657.
11. 11 Visvader JE, Venter D, Hahm K, Santamaria M, Sum EYM, O'Reilly L, White D, Williams R, Armes J, Lindeman GJ. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci USA 2001 ; 98: 14452–14457.
12. 12 Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia oncoprotein SCL/tal‐1 is essential for development of all hematopoietic lineages. Cell 1996 ; 86: 47–57.
13. 13 Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998 ; 95: 3890–3895.
14. 14 Robb L, Elwood NJ, Elefanty AG, Kontgen F, Li R, Barnett LD, Begley CG. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J 1996 ; 15: 4123–4129.
15. 15 Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine‐rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994 ; 78: 45–57.
16. 16 Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A, Rabbitts TH. The LIM‐only protein Lmo2 is a bridging molecule assembling an erythroid, DNA‐binding complex which includes the TAL1, E47, GATA‐1 and Ldb1/NLI proteins. EMBO J 1997 ; 16: 3145–3157.
17. 17 Valge‐Archer VE, Osada H, Warren AJ, Forster A, Li J, Baer R, Rabbitts TH. The LIM protein RBTN2 and the basic helix‐loop‐helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci USA 1994 ; 91: 8617–8621.
18. 18 Grutz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T cell LIM‐protein Lmo2 forms part of a DNA‐binding complex specifically in immature T cells. EMBO J 1998 ; 17: 4594–4605.
19. 19 Lahlil R, Lecuyer E, Herblot S, Hoang T. SCL assembles a multifactorial complex that determines glycophorin A expression. Mol Cell Biol 2004 ; 24: 1439–1452.
20. 20 Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL, Chun J, Huey B, Pinkel D, Murre C. E2A deficiency leads to abnormalities in αβ T‐cell development and to rapid development of T‐cell lymphomas. Mol Cell Biol 1997 ; 17: 4782–4791.
21. 21 O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004 ; 5: 587–596.
22. 22 O'Neil J, Billa M, Oikemus S, Kelliher M. The DNA binding activity of TAL‐1 is not required to induce leukemia/lymphoma in mice. Oncogene 2001 ; 20: 3897–3905.
23. 23 Goldfarb AN, Lewandowska K. Inhibition of cellular differentiation by the SCL/tal oncoprotein: transcriptional repression by an Id‐like mechanism. Blood 1995 ; 85: 465–471.
24. 24 Ryan DP, Sunde M, Kwan AH, Marianayagam NJ, Nancarrow AL, vanden Hoven RN, Thompson LS, Baca M, Mackay JP, Visvader JE, Matthews JM. Identification of the key LMO2‐binding determinants on Ldb1. J Mol Biol 2006 ; 359: 66–75.
25. 25 Murphy JB, Kies MW. Note on spectrophotometric determination of proteins in dilute solutions. Biochim Biophys Acta 1960 ; 45: 382–384.
26. 26 Sreerama N, Woody RW. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem 2000 ; 287: 252–260.
27. 27 Folta‐Stogniew E, Williams K. Determination of molecular masses of proteins in solution: implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory. J Biomol Tech 1999 ; 10: 51–63.
28. 28 Manickam DS, Bisht HS, Wan L, Mao G, Oupicky D. Influence of TAT‐peptide polymerization on properties and transfection activity of TAT/DNA polyplexes. J Control Release 2005 ; 102: 293–306.
29. 29 Johnson ML, Correia JJ, Yphantis DA, Halvorson HR. Analysis of data from the analytical ultracentrifuge by nonlinear least‐squares techniques. Biophys J 1981 ; 36: 575–588.
30. 30 Brown PH, Schuck P. Macromolecular size‐and‐shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J 2006 ; 90: 4651–4661.
31. 31 Hayes DB, Laue T, Philo J. SEDNTERP. USA: University of New Hampshire ; 1995.
32. 32 Mulquiney PJ, Kuchel PW. Model of 2,3‐bisphosphoglycerate metabolism in the human erythrocyte based on detailed enzyme kinetic equations: computer simulation and metabolic control analysis. Biochem J 1999 ; 342 (Part 3): 597–604.
33. 33 Mulquiney PJ, Kuchel PW. Modelling metabolism with mathematica. Boca Raton, FL: CRC Press ; 2003. 309 p.
34. 34 Deane JE, Sum E, Mackay JP, Lindeman GJ, Visvader JE, Matthews JM. Design, production and characterization of FLIN2 and FLIN4: the engineering of intramolecular ldb1: LMO complexes. Protein Eng 2001 ; 14: 493–499.
35. 35 Deane JE, Ryan DP, Sunde M, Maher MJ, Guss JM, Visvader JE, Matthews JM. Tandem LIM domains provide synergistic binding in the LMO4: Ldb1 complex. EMBO J 2004 ; 23: 3589–3598.
36. 36 Erijman L, Lorimer GH, Weber G. Reversible dissociation and conformational stability of dimeric ribulose bisphosphate carboxylase. Biochemistry 1993 ; 32: 5187–5195.
37. 37 Silva JL, Silveira CF, Junior AC, Pontes L. Dissociation of a native dimer to a molten globule monomer. Effects of pressure and dilution on the association equilibrium of arc repressor. J Mol Biol 1992 ; 223: 545–555.
38. 38 Xu G, Weber G. Dynamics and time‐averaged chemical potential of proteins: importance in oligomer association. Proc Natl Acad Sci USA 1982 ; 79: 5268–5271.
39. 39 Kunne AG, Allemann RK. Covalently linking BHLH subunits of MASH‐1 increases specificity of DNA binding. Biochemistry 1997 ; 36: 1085–1091.
40. 40 Wendt H, Thomas RM, Ellenberger T. DNA‐mediated folding and assembly of MyoD‐E47 heterodimers. J Biol Chem 1998 ; 273: 5735–5743.
41. 41 Maleki SJ, Royer CA, Hurlburt BK. MyoD‐E12 heterodimers and MyoD‐MyoD homodimers are equally stable. Biochemistry 1997 ; 36: 6762–6767.
42. 42 Osada H, Grutz G, Axelson H, Forster A, Rabbitts TH. Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc‐finger protein GATA1. Proc Natl Acad Sci USA 1995 ; 92: 9585–9589.
43. 43 Hsu HL, Huang L, Tsan JT, Funk W, Wright WE, Hu JS, Kingston RE, Baer R. Preferred sequences for DNA recognition by the TAL1 helix‐loop‐helix proteins. Mol Cell Biol 1994 ; 14: 1256–1265.
44. 44 Wadman I, Li J, Bash RO, Forster A, Osada H, Rabbitts TH, Baer R. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J 1994 ; 13: 4831–4839.
45. 45 Yang VW. Eukaryotic transcription factors: identification, characterization and functions. J Nutr 1998 ; 128: 2045–2051.
46. 46 Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A‐HEB function and pre‐T α chain expression. Nat Immunol 2000 ; 1: 138–144.
47. 47 Orkin SH. Priming the hematopoietic pump. Immunity 2003 ; 19: 633–634.
48. 48 Enver T, Greaves M. Loops, lineage, and leukemia. Cell 1998 ; 94: 9–12.
49. 49 Gering M, Rodaway AR, Gottgens B, Patient RK, Green AR. The SCL gene specifies haemangioblast development from early mesoderm. EMBO J 1998 ; 17: 4029–4045.
50. 50 Gering M, Yamada Y, Rabbitts TH, Patient RK. Lmo2 and Scl/Tal1 convert non‐axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development 2003 ; 130: 6187–6199.
51. 51 Porcher C, Liao EC, Fujiwara Y, Zon LI, Orkin SH. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development 1999 ; 126: 4603–4615.
52. 52 Ravet E, Reynaud D, Titeux M, Izac B, Fichelson S, Romeo PH, Dubart‐Kupperschmitt A, Pflumio F. Characterization of DNA‐binding‐dependent and ‐independent functions of SCL/TAL1 during human erythropoiesis. Blood 2004 ; 103: 3326–3335.
53. 53 Xu Z, Huang S, Chang LS, Agulnick AD, Brandt SJ. Identification of a TAL1 target gene reveals a positive role for the LIM domain‐binding protein Ldb1 in erythroid gene expression and differentiation. Mol Cell Biol 2003 ; 23: 7585–7599.
54. 54 Gould KA, Bresnick EH. Sequence determinants of DNA binding by the hematopoietic helix‐loop‐helix transcription factor TAL1: importance of sequences flanking the E‐box core. Gene Expr 1998 ; 7: 87–101.
55. 55 Beltran AC, Dawson PE, Gottesfeld JM. Role of DNA sequence in the binding specificity of synthetic basic‐helix‐loop‐helix domains. Chembiochem 2005 ; 6: 104–113.
56. 56 Omichinski JG, Trainor C, Evans T, Gronenborn AM, Clore GM, Felsenfeld G. A small single‐“finger” peptide from the erythroid transcription factor GATA‐1 binds specifically to DNA as a zinc or iron complex. Proc Natl Acad Sci USA 1993 ; 90: 1676–1680.
57. 57 Prasad KS, Brandt SJ. Target‐dependent effect of phosphorylation on the DNA binding activity of the TAL1/SCL oncoprotein. J Biol Chem 1997 ; 272: 11457–11462.